Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60

Cellular and Molecular Immunology

Volumn 11, Issue 3, 2014, Pages 285-293

  Yang, Jing ^a,b   Wang, Qun ^c   Qiao, Chunxia ^a   Lin, Zhou ^a   Li, Xinying ^a   Huang, Yifei ^c   Zhou, Tingting ^a   Li, Yan ^a   Shen, Beifen ^a   Lv, Ming ^a   Feng, Jiannan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

angiogenesis; anti VEGF antibody; cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; MIL60 ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTIBODY; EPITOPE; NEUTRALIZING ANTIBODY; PROTEIN BINDING; VASCULOTROPIN A; MIL 60 ANTIBODY;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL MIGRATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; OVARY CANCER; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MICROVASCULATURE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; CONCENTRATION RESPONSE; DRUG STRUCTURE; ENDOTHELIUM CELL; HT 29 CELL LINE; MITOSIS INHIBITION; MOUSE; OVARY CARCINOMA; PROTEIN BINDING; PROTEIN PHOSPHORYLATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; EPITOPES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84899866137     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2014.6     Document Type: Article

References (32)

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
2. Ichihara E, Kiura K, Tanimoto M. Targeting angiogenesis in cancer therapy. Acta Med Okayama 2011; 65: 353-362.
3. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 1999; 77: 527-543.
4. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259-270.
5. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
6. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-5218.
7. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
8. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000; 60: 6253-6258.
9. Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004; 4(Suppl 2): S81-S85.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
11. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: A new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005; 2: 562-577.
12. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
13. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
14. McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci USA 2012; 109: 18281-18289.
15. Sullivan LA, Brekken RA. The VEGF family in cancer and antibodybased strategies for their inhibition. MAbs 2010; 2: 165-175.
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
17. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
18. Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, Roux B et al. CHARMM: The biomolecular simulation program. J Comput Chem 2009; 30: 1545-1614.
19. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, OgawaMet al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858-863.
20. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-1887.
21. Higgins B, Kolinsky K, Linn M, Adames V, Zhang YE, Moisa C et al. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res 2007; 27: 2279-2287.
22. Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marme D et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004; 6: 248-257.
23. Qiao C, Lv M, Li X, Geng J, Li Y, Zhang J et al. Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design. J Biomol Struct Dyn 2013; 31: 511-521.
24. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185.
25. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
26. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7: 53-64.
27. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-132.
28. Yu Y, Lee P, Ke Y, Zhang Y, Yu Q, Lee J et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS ONE 2010; 5: E9072.
29. Ferla R, Bonomi M, Otvos L Jr, Surmacz E. Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: Comparison with VEGF effects. BMC Cancer 2011; 11: 303.
30. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-345.
31. Jain RK. Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology (Williston Park) 2005; 19: 7-16.
32. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007; 104: 3478-3483.